Alzheimer's disease drug discovery: In vivo screening using Caenorhabditis elegans as a model for β-amyloid peptide-induced toxicity

Drug Discovery Today: Technologies

Volumn 10, Issue 1, 2013, Pages

  Lublin, A L ^a   Link, C D ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BACITRACIN; CAFFEINE; EPIGALLOCATECHIN GALLATE; FLUOXETINE; GINKGO BILOBA EXTRACT; GLYCITEIN; MIANSERIN; RESERPINE; TANNIN; TAU PROTEIN; THIOFLAVINE;

ALZHEIMER DISEASE; CAENORHABDITIS ELEGANS; CELL CULTURE; DRUG MECHANISM; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; PROTEIN ANALYSIS; REVIEW; RNA INTERFERENCE; STRAIN DIFFERENCE; TOXICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS;

EID: 84875693819     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2012.02.002     Document Type: Review

References (35)

1. A.L. Lublin, and S. Gandy Amyloid-β oligomers: possible roles as key neurotoxins in Alzheimer's disease Mount Sinai J. Med.: J. Transl. Pers. Med. 77 2010 43 49
2. C. Haass, and D.J. Selkoe Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide Nat. Rev. Mol. Cell Biol. 8 2007 101 112
3. J. Naslund Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline JAMA 283 2000 1571 1577
4. M.P. Lambert Diffusible: nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. U. S. A. 95 1998 6448 6453
5. A. Lublin FDA-approved drugs that protect mammalian neurons from glucose toxicity slow aging dependent on Cbp and protect against proteotoxicity PLoS One 6 2011 e27762
6. A.R. Burns A predictive model for drug bioaccumulation and bioactivity in Caenorhabditis elegans Nat. Chem. Biol. 6 2010 549 557
7. M. Petrascheck An antidepressant that extends lifespan in adult Caenorhabditis elegans Nature 450 2007 553 556
8. S. Brenner The genetics of Caenorhabditis elegans Genetics 77 1974 71 94
9. C.D. Link Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans Proc. Natl. Acad. Sci. U. S. A. 92 1995 9368 9372
10. G. McColl The Caenorhabditis elegans Aβ1-42 model of Alzheimer disease predominantly expresses Aβ3-42 J. Biol. Chem. 284 2009 22697 22702
11. D.S. Fay In vivo aggregation of β-amyloid peptide variants J. Neurochem. 71 1998 1616 1625
12. J.V. Smith, and Y. Luo Elevation of oxidative free radicals in Alzheimer's disease models can be attenuated by Ginkgo biloba extract EGb 761 J. Alzheimer Dis. 5 2003 287 300
13. A. Gutierrez-Zepeda Soy isoflavone glycitein protects against beta amyloid-induced toxicity and oxidative stress in transgenic Caenorhabditis elegans BMC Neurosci 6 2005 54
14. S. Abbas, and M. Wink Epigallocatechin gallate inhibits beta amyloid oligomerization in Caenorhabditis elegans and affects the daf-2/insulin-like signaling pathway Phytomedicine 17 2010 902 909
15. U. Arya Reserpine ameliorates Abeta toxicity in the Alzheimer's disease model in Caenorhabditis elegans Exp. Gerontol. 44 2009 462 466
16. R. Keowkase Fluoxetine protects against amyloid-beta toxicity, in part via daf-16 mediated cell signaling pathway, in Caenorhabditis elegans Neuropharmacology 59 2010 358 365
17. S. Alavez Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan Nature 472 2011 226 229
18. E. Cohen Opposing activities protect against age-onset proteotoxicity Science 313 2006 1604 1610
19. C.D. Link Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model Neurobiol. Aging 24 2003 397 413
20. V. Dostal, and C.D. Link Assaying beta-amyloid toxicity using a transgenic C. elegans model J. Vis. Exp. 2010
21. V. Dostal Genetic mechanisms of coffee extract protection in a Caenorhabditis elegans model of beta-amyloid peptide toxicity Genetics 186 2010 857 866
22. L. Diomede Tetracycline and its analogues protect Caenorhabditis elegans from beta amyloid-induced toxicity by targeting oligomers Neurobiol. Dis. 40 2010 424 431
23. Y. Wu Amyloid-β-induced pathological behaviors are suppressed by ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans J. Neurosci. 26 2006 13102 13113
24. L.E. Dosanjh Behavioral phenotyping of a transgenic Caenorhabditis elegans expressing neuronal amyloid-beta J. Alzheimer Dis. 19 2010 681 690
25. S. Treusch Functional Links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast Science 2011
26. B.C. Kraemer Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy Proc. Natl. Acad. Sci. U. S. A. 100 2003 9980 9985
27. R. Brandt A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau Neurobiol. Aging 30 2009 22 33
28. T. Miyasaka Progressive neurodegeneration in C. elegans model of tauopathy Neurobiol. Dis. 20 2005 372 383
29. S.D. Buckingham, and D.B. Sattelle Strategies for automated analysis of C. elegans locomotion Invert. Neurosci. 8 2008 121 131
30. D.L. Rebolledo Copper reduces Aβ oligomeric species and ameliorates neuromuscular synaptic defects in a C. elegans model of inclusion body myositis J. Neurosci. 31 2011 10149 10158
31. C.Y. Ewald, and C. Li Caenorhabditis elegans as a model organism to study APP function Exp. Brain Res. 2011
32. G. Vattemi Amyloid-β42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis Acta Neuropathol. (Berl.) 117 2009 569 574
33. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies Lancet 372 2008 293 299
34. L.E. Hebert Alzheimer disease in the US population: prevalence estimates using the 2000 census Arch. Neurol. 60 2003 1119 1122
35. V. Fonte Interaction of intracellular beta amyloid peptide with chaperone proteins Proc. Natl. Acad. Sci. U. S. A. 99 2002 9439 9444